北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 眼科  > 期刊论文
学科主题: 临床医学
题名:
Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study
作者: Hou Jing; Tao Yong; Jiang Yan-rong; Li Xiao-xin; Gao Lei
关键词: bevacizumab ; branch retinal vein occlusion ; triamcinolone acetonide
刊名: CHINESE MEDICAL JOURNAL
发表日期: 2009-11-20
DOI: 10.3760/cma.j.issn.0366-6999.2009.22.004
卷: 122, 期:22, 页:2695-2699
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: INTRAOCULAR-PRESSURE ELEVATION ; NEOVASCULAR DISEASES ; SECONDARY ; AVASTIN ; INJECTION
英文摘要:

Background Branch retinal vein occlusion (BRVO) is a common retinal vascular disorder of the elderly and both intravitreal triamcinolone acetonide (TA) and intravitreal bevacizumab were reported to be effective. The purpose of this study was to compare intravitreal bevacizumab with intravitreal TA for the treatment of macular edema resulting from BRVO.

Methods The retrospectively comparative interventional study included a bevacizumab group of 34 BRVO patients (1.25 mg bevacizumab) and a TA group of 34 BRVO patients (4.0 mg TA), and the two groups were matched by baseline best corrected visual acuity (BCVA). Examinations were designed to be carried out at 1 day, 3 days, 1 month, 2 months, 3 months, 6 months and 1 year after each injection. The mean follow-up was (148.43 +/- 130.56) days. Main outcome parameters were BCVA and morphometric measurements of the macula obtained by optical coherence tomography.

Results In all follow-ups, the mean changes of BCVA (LogMAR) between two groups were not significantly different (P>0.10). Similarly, the rates of patients who got BCVA improvement >= 2 lines or lost BCVA >= 2 lines were not significantly different, either (P>0.10). In both groups, compared with baseline, the mean central macular thickness (CMT) got reduction from 4 weeks to 1 year after initial injection, however, which lost statistical significance at 6-month follow-up in TA group (P=0.25) and lost significance at 3-month and 6-month follow-up in bevacizumab group (P=0.07, 0.21). The mean CMT between two groups differed at 3-month follow-up (P<0.01), while almost kept parallel in other follow-ups (all P>0.40). In TA group, retinal pigment epithelium tear occurred in 1 eye at 8 weeks after initial injection and 12 eyes (35.3%) got intraocular pressure >21 mmHg. In bevacizumab group, no severe complications were observed.

Conclusion For BRVO, intravitreal bevacizumab versus intravitreal TA causes a similar increase in visual acuity and reduction of macular edema (except 3-month follow-up) with minor complications during 1 year. Chin Med J 2009;122(22):2695-2699

语种: 英语
所属项目编号: 7062065
项目资助者: Beijing Natural Science Foundation
WOS记录号: WOS:000272580300004
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/66293
Appears in Collections:北京大学第二临床医学院_眼科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China

Recommended Citation:
Hou Jing,Tao Yong,Jiang Yan-rong,et al. Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: a matched study[J]. CHINESE MEDICAL JOURNAL,2009,122(22):2695-2699.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Hou Jing]'s Articles
[Tao Yong]'s Articles
[Jiang Yan-rong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Hou Jing]‘s Articles
[Tao Yong]‘s Articles
[Jiang Yan-rong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace